NCT06323174

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 189 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Cagrilintide	Participants will receive once-weekly cagrilintide subcutaneously.
DRUG	Semaglutide	Participants will receive once-weekly semaglutide subcutaneously.
DRUG	Placebo	Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Timeline

• Start date: 2024-03-19
• Primary completion: 2025-10-01
• Completion: 2025-12-22
• First posted: 2024-03-21
• Last updated: 2026-04-02

Locations

50 sites across 7 countries: United States, China, Hungary, Italy, Poland, Saudi Arabia, Serbia

Regulatory

• FDA-regulated drug study